Swiss pharmaceutical company Novartis has announced an agreement to acquire a breast cancer drug candidate from U.S. biotech firm Synnovation Therapeutics for a total of up to $3 billion. This acquisition is poised to enhance Novartis’ pipeline of cancer therapies, particularly in the area of targeted treatments.
The deal includes an upfront payment of $2 billion, with the potential for an additional $1 billion contingent upon achieving certain development milestones. The drug in question, SNV4818, is classified as a selective PI3Kα inhibitor, representing a novel approach in the treatment of HR positive/HER2 negative breast cancer, as well as potentially other solid tumours.
SNV4818 is currently undergoing early-stage clinical trials and has demonstrated promising activity against tumours in laboratory studies. Novartis has expressed optimism regarding the drug’s targeted mechanism, which focuses solely on the mutated form of the PI3Kα enzyme—a known contributor to breast cancer and other malignancies—while leaving healthy cells unaffected. This specificity aims to mitigate the side effects typically associated with existing PI3Kα-inhibiting therapies.
Shreeram Aradhye, Chief Medical Officer at Novartis, stated, “While mutated PI3Kα is a well-established driver in HR+/HER2- breast cancer, there remains a challenge in achieving effective pathway inhibition with a tolerable therapeutic profile.” This underscores the importance of continued innovation in cancer treatment.
Novartis anticipates that the transaction will be finalised in the first half of this year, further solidifying its commitment to advancing innovative cancer therapies. As the landscape of oncology treatment continues to evolve, the integration of such targeted therapies will play a crucial role in addressing the complexities of cancer care.